ADULT COVID-19 2025-2026
ID: 75D30125R00117Type: Combined Synopsis/Solicitation
Overview

Buyer

HEALTH AND HUMAN SERVICES, DEPARTMENT OFCENTERS FOR DISEASE CONTROL AND PREVENTIONCDC OFFICE OF ACQUISITION SERVICESATLANTA, GA, 30333, USA

NAICS

Pharmaceutical Preparation Manufacturing (325412)

PSC

DRUGS AND BIOLOGICALS (6505)

Original Source

https://sam.gov/opp/7b9b5e58beae4e62975a66f4de7ece35/view
Timeline
    Description

    The Centers for Disease Control and Prevention (CDC) is seeking proposals for one or more Indefinite Delivery Indefinite Quantity (IDIQ) contracts to purchase U.S.-licensed COVID-19 vaccines specifically for adults aged 19 and older. The objective of this procurement is to leverage Section 317 vaccine purchase funds to acquire vaccines at prices lower than those available in the commercial market, thereby supporting state and local health departments in immunizing populations at risk of under-vaccination. This initiative is crucial for enhancing adult immunization coverage and ensuring effective public health practices, as the awarded vaccines will be distributed to health departments and programs across the United States, including territories. Interested suppliers should contact Brian Swann at qty0@cdc.gov or James Sprigler at zbs6@cdc.gov for further details, with a maximum procurement potential of 10 million doses and specific ordering requirements outlined in the solicitation documents.

    Point(s) of Contact
    Brian Swann
    qty0@cdc.gov
    James Sprigler
    zbs6@cdc.gov
    Files
    Title
    Posted
    Attachment 1 - Vaccine Order Limitation Chart.docx
    The document outlines a federal Request for Proposals (RFP) for adult COVID-19 vaccines, specifically targeting individuals aged 19 and older. It specifies the minimum order size of 100 doses and highlights the federal excise tax of $0.75 per dose. The maximum potential procurement is noted at 10 million doses, with the total cost calculated including the excise tax. This RFP is part of the government's ongoing efforts to ensure vaccine availability for adults, emphasizing the structured approach to procurement to meet public health needs. By clearly delineating the costs and order requirements, the document facilitates the bidding process for suppliers while ensuring compliance with federal guidelines.
    Attachment 2 - ADR Agreement.docx
    The Authorized Distributor of Record (ADR) Agreement formalizes the relationship between a supplier and the Centers for Disease Control and Prevention (CDC), designating the CDC as an authorized distributor under the Prescription Drug Marketing Act (PDMA) of 1988 and associated regulations. The agreement requires that the supplier lists all specific products authorized for distribution or confirms that the CDC is designated for the entire product line. The validity of the agreement extends until termination, which can occur with a 90-day notice. It clarifies that the CDC's designation does not provide any rights beyond this ADR status and does not replace any existing or future distribution agreements. Both parties must sign to acknowledge and agree to adhere to these terms. A list of products is to be included as an attachment, specifying details such as product names, dosages, and National Drug Code (NDC) numbers. This document outlines the framework for regulatory compliance and partnership between the supplier and the CDC, pertinent to the distribution of pharmaceuticals and vaccines under federal guidelines.
    Solicitation 75D30125R00117 COVID19 Adult.pdf
    The Centers for Disease Control and Prevention (CDC) is soliciting bids for one or more Indefinite Delivery Indefinite Quantity (IDIQ) contracts to purchase U.S.-licensed COVID-19 vaccines for adults. The goal is to leverage Section 317 vaccine purchase funds to obtain vaccines at discounted prices for state and local health departments, particularly for populations at risk of under-vaccination. These contracts enable the CDC to facilitate adult immunization through the National Center for Immunization and Respiratory Diseases (NCIRD). The contract outlines the requirements for vaccine delivery, including minimum shelf life, packaging, and maintenance of FDA-recommended temperatures. Additionally, it details the ordering process via the Vaccine Tracking System (VTrckS) and specifies payment terms, including electronic funds transfer. Contractors must provide advance notice for supply issues and maintain reporting protocols for sales data. The document emphasizes compliance with public health laws, quality standards, and the prohibition of resale of the vaccines obtained under these contracts. It highlights the collaboration between federal, state, and local health entities to ensure effective immunization practices, aiming to achieve higher vaccination coverage among adults.
    Solicitation 75D30125R00117 COVID19 Adult Pages 2-50.docx
    The Centers for Disease Control and Prevention (CDC) is issuing a Request for Proposals (RFP) for the establishment of Indefinite Delivery Indefinite Quantity (IDIQ) contracts aimed at acquiring U.S.-licensed COVID-19 vaccines for adults. The contracts will utilize Section 317 vaccine purchase funds, allowing purchases below commercial market prices for state and local health departments serving at-risk populations. The awarded vaccines will support adult immunization programs across state health departments, large city programs, and U.S. territories. The contract requires adherence to specific conditions, including a minimum shelf life of 12 months for vaccines and strict temperature controls during transit. Orders will be facilitated through the Vaccine Tracking System (VTrckS), with processes established to ensure fair opportunity for contractors based on clinical appropriateness, local advisory recommendations, and available funding. Key considerations also include restrictions on vaccine use solely for immunization purposes for adults aged 19 and older, and explicit prohibitions against resale or free distribution. The CDC aims to adapt the contracts to future vaccine developments and maintain purchasing parity with commercial markets, ensuring ongoing access to effective COVID-19 vaccinations for public health initiatives.
    Lifecycle
    Title
    Type
    ADULT COVID-19 2025-2026
    Currently viewing
    Combined Synopsis/Solicitation
    Similar Opportunities
    Geneious Prime Enterprise Licenses
    Health And Human Services, Department Of
    The Department of Health and Human Services, specifically the Centers for Disease Control and Prevention (CDC), is seeking to award a sole source firm fixed price contract to Graphpad Software LLC for the procurement of Geneious Prime Enterprise Academic Yearly Subscription, covering 200 seats. This software licensing is critical as it is integrated into several validated CLIA test protocols, and the government is unable to modify these protocols due to time and cost constraints. The anticipated period of performance for this contract is from February 23, 2026, to February 22, 2031, with the possibility of four one-year option periods. Interested vendors are encouraged to express their interest and capability by submitting proposals to the Contracting Officer at xur0@cdc.gov by 5:00 PM (ET) on December 16, 2025.
    National Immunization Survey - Flu Q2-Q4 2023 Bridge Contract
    Health And Human Services, Department Of
    The Department of Health and Human Services, specifically the Centers for Disease Control and Prevention (CDC), is seeking to continue the National Immunization Survey through a bridge contract for the second to fourth quarters of 2023. This contract, awarded to the National Opinion Research Center (NORC), aims to ensure the timely collection and analysis of immunization data, which is critical for public health decision-making and policy formulation. The justification for this contract was made under the authority of FAR 6.302-2 due to unusual and compelling urgency, and the associated Justification and Approval for Other Than Full and Open Competition (JOFOC) will be available for review for 30 days following the contract award. For further inquiries, interested parties may contact Joshua Houston at pkf5@cdc.gov.
    Notice of Intent to Sole Source Modification of Contract to Quest Diagnostics, Inc.
    Health And Human Services, Department Of
    The Department of Health and Human Services, specifically the Centers for Disease Control and Prevention (CDC), intends to negotiate a non-competitive modification to an existing contract with Quest Diagnostics, Inc. This modification aims to expand the scope of the contract to include access to de-identified antibody results from previously tested specimens, focusing on individuals with immunocompromising conditions as part of the CDC's Multistate Assessment of SARS-CoV-2 Seroprevalence in Commercial Laboratory Survey (MASS-C) Study. The contract modification is crucial for estimating the prevalence of SARS-CoV-2 infections and vaccinations across various demographics and geographic locations, utilizing existing data rather than incurring additional costs for new specimen collection. Interested parties may submit responses to this notice within 15 days to the primary contact, Liz Cole-Greenblatt, at qst7@cdc.gov, although the government retains discretion over whether to pursue competitive procurement.
    National Immunization Survey - Child Q2-Q4 2023 Bridge Contract
    Health And Human Services, Department Of
    The Department of Health and Human Services, specifically the Centers for Disease Control and Prevention (CDC), has awarded a bridge contract for the National Immunization Survey covering the second to fourth quarters of 2023. This contract, awarded to the National Opinion Research Center (NORC), aims to continue essential data collection and analysis related to immunization rates among children, which is critical for public health monitoring and policy-making. The contract was issued under the authority of FAR 6.302-2 due to unusual and compelling urgency, and the justification for this non-competitive award will be available for review for 30 days following the award date. For further inquiries, interested parties can contact Joshua Houston at pkf5@cdc.gov.
    J&A Procurement of Smallpox (Mpox) Vaccine for the Strategic National Stockpile
    Health And Human Services, Department Of
    The Department of Health and Human Services, specifically the Office of Assistant Secretary for Preparedness and Response (BARDA), is seeking to procure additional doses of the JYNNEOS™ vaccine for the Strategic National Stockpile in response to the ongoing monkeypox outbreak. The procurement aims to rapidly secure 11 million doses of the vaccine by utilizing existing bulk drug substance and to enhance manufacturing capacity through technology transfer to contract manufacturing organizations. The JYNNEOS™ vaccine is critical as it is the only licensed vaccine for both smallpox and monkeypox, making it essential for public health preparedness. Interested parties can contact Yifan Yang at yifan.yang@hhs.gov, with the total estimated value of the contract modification being $992,400,000.
    Request for Information - Software Licenses for Digital Evaluation and Analysis
    Health And Human Services, Department Of
    The Department of Health and Human Services, specifically the Centers for Disease Control and Prevention (CDC), is seeking responses to a Request for Information (RFI) for software licenses related to a digital evaluation and analysis platform. The objective is to procure license subscription access that enables rapid, remote user testing on both desktop and mobile platforms, incorporating various testing methodologies, including unmoderated and moderated tests with participants from a Contributor Network of public health professionals. This platform is crucial for enhancing the usability of CDC digital content and must comply with IT security, PII, and Section 508 accessibility standards. Interested vendors should submit their responses, including company information and comments on the draft Statement of Work, by January 7, 2026, and can direct inquiries to Jennifer Gartzke at xuy7@cdc.gov or by phone at 404-498-0020.
    GMP Manufacturing of CDC FluSC2 Multiplex EUA Kit
    Health And Human Services, Department Of
    The Department of Health and Human Services, specifically the Centers for Disease Control and Prevention (CDC), has awarded a contract for the GMP manufacturing of the CDC FluSC2 Multiplex EUA Kit to Biosearch Technologies, Inc. This contract, valued at $399,993, entails the production of 1,020 vials of oligonucleotide primers and probes, adhering to Good Manufacturing Practices (GMP) as defined under 21 CFR 820, with a required delivery date of September 25, 2023. The specific internal BHQnova quencher design of the probes is critical for the diagnostic assay, which has received Emergency Use Authorization (EUA) from the FDA, and no other suppliers have been identified that can meet these stringent requirements. For further inquiries, interested parties may contact Mark Draluck at syq1@cdc.gov or Devin Barich at uca9@cdc.gov.
    National Immunization Survey - Teen Q2-Q4 2023 Bridge Contract
    Health And Human Services, Department Of
    The Department of Health and Human Services, specifically the Centers for Disease Control and Prevention (CDC), has awarded a bridge contract for the National Immunization Survey - Teen for Q2-Q4 2023 to the National Opinion Research Center (NORC). This contract, awarded under the authority of FAR 6.302-2 due to unusual and compelling urgency, aims to continue essential data collection and analysis related to teen immunization rates. The justification for this contract is being made available in accordance with federal regulations, highlighting the importance of timely data for public health initiatives. For further inquiries, interested parties can contact Joshua Houston at pkf5@cdc.gov, with the justification document available for review for 30 days following the contract award.
    Serological Assays for the Detection and Characterization of Influenza Viruses
    Health And Human Services, Department Of
    The Department of Health and Human Services, specifically the Centers for Disease Control and Prevention (CDC), is seeking proposals for "Serological Assays for the Detection and Characterization of Influenza Viruses." The procurement aims to secure services for performing Hemagglutinin Inhibition (HAI) assays on approximately 6,000 human samples annually, with the potential for surge support up to 10,500 tests, alongside the development of new high-throughput serology assays. This initiative is crucial for enhancing the CDC's capabilities in monitoring and responding to influenza outbreaks. Interested parties should note that the solicitation has been reopened, with key deadlines extended, and are encouraged to contact Jennifer Gartzke at jgartzke@cdc.gov for contractual inquiries. The contract will span a base period of 12 months with four additional option years, and all work must comply with Section 508 accessibility standards.
    LSJ for DHIS Management and Consulting Services MOD 00002
    Health And Human Services, Department Of
    The Department of Health and Human Services, specifically the Centers for Disease Control and Prevention (CDC), is seeking to modify an existing contract for DHIS Management and Consulting Services under Task Order 75D30122F15055. The modification, labeled as MOD 00002, aims to increase the level of effort for Task 4.4.4 and reclassify Task 4.4.5 as an optional task for both base and option periods, reflecting the need for enhanced support due to the involvement of multiple stakeholders in related programs. This procurement is crucial for the effective management of the CDC Data Hub and Electronic Case Reporting initiatives, ensuring that the necessary resources are allocated to meet the demands of these programs. Interested parties can reach out to Marie Bartkevicius at vgj6@cdc.gov or 770-488-8493, or Lauren Peel at ijt9@cdc.gov or 770-488-2649 for further information regarding this opportunity.